Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to …
AC Correia, AR Monteiro, R Silva, JN Moreira… - Advanced Drug Delivery …, 2022 - Elsevier
The main limitation to the success of central nervous system (CNS) therapies lies in the
difficulty for drugs to cross the blood–brain barrier (BBB) and reach the brain. Regarding its …
difficulty for drugs to cross the blood–brain barrier (BBB) and reach the brain. Regarding its …
Cannabinoid formulations and delivery systems: Current and future options to treat pain
B Stella, F Baratta, C Della Pepa, S Arpicco, D Gastaldi… - Drugs, 2021 - Springer
The field of Cannabis sativa L. research for medical purposes has been rapidly advancing in
recent decades and a growing body of evidence suggests that phytocannabinoids are …
recent decades and a growing body of evidence suggests that phytocannabinoids are …
Promising nanocarriers to enhance solubility and bioavailability of cannabidiol for a plethora of therapeutic opportunities
In recent years, the interest in cannabidiol (CBD) has increased because of the lack of
psychoactive properties. However, CBD has low solubility and bioavailability, variable …
psychoactive properties. However, CBD has low solubility and bioavailability, variable …
Recent advances in intranasal liposomes for drug, gene, and vaccine delivery
Liposomes are safe, biocompatible, and biodegradable spherical nanosized vesicles
produced from cholesterol and phospholipids. Recently, liposomes have been widely …
produced from cholesterol and phospholipids. Recently, liposomes have been widely …
Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain delivery
TTL Nguyen, HJ Maeng - Pharmaceutics, 2022 - mdpi.com
Nose-to-brain drug delivery has been of great interest for the treatment of many central
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …
[HTML][HTML] The use of cannabinoids in the treatment of inflammatory bowel disease (IBD): a review of the literature
BN Nduma, KA Mofor, J Tatang, C Ekhator, S Ambe… - Cureus, 2023 - ncbi.nlm.nih.gov
Around the world, about 15 to 40% of individuals with inflammatory bowel disease (IBD) rely
on cannabis and cannabinoids to reduce the need for other medications, as well as increase …
on cannabis and cannabinoids to reduce the need for other medications, as well as increase …
A cannabidiol-containing alginate based hydrogel as novel multifunctional wound dressing for promoting wound healing
In addition to preventing infection and promoting angiogenesis, novel hydrogel dressings
are highly expected to possess the potential to scavenge reactive oxygen species (ROS) …
are highly expected to possess the potential to scavenge reactive oxygen species (ROS) …
Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits
Neurodegenerative disorders (NDs) such as Alzheimer's disease, Parkinson's disease,
Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis are severe and …
Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis are severe and …
Development of stable nano-sized transfersomes as a rectal colloid for enhanced delivery of cannabidiol
Current cannabidiol (CBD) formulations are challenged with unpredictable release and
absorption. Rational design of a rectal colloid delivery system can provide a practical …
absorption. Rational design of a rectal colloid delivery system can provide a practical …
Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids
Medical cannabis has received significant interest in recent years due to its promising
benefits in the management of pain, anxiety, depression and neurological and movement …
benefits in the management of pain, anxiety, depression and neurological and movement …